Immune alterations in malignant melanoma and current immunotherapy concepts

Expert Opinion on Biological Therapy

Volumn 13, Issue 10, 2013, Pages 1413-1427

  Shimanovsky, Alexei ^a   Jethava, Ashif ^b   Dasanu, Constantin A ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Anti CTLA 4 antibodies; Anti PD 1 antibodies; Immunotherapy; Ipil; Malignant melanoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; INTERLEUKIN 2; IPILIMUMAB; LAMBROLIZUMAB; MPDL 3280A; NIVOLUMAB; SIPULEUCEL T; TICILIMUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CUTANEOUS MELANOMA; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEVER; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MACROPHAGE; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MYALGIA; NATURAL KILLER CELL; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RASH; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 84884270901     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.827658     Document Type: Review

References (156)

1. Ingraffea A. Melanoma. Facial Plast Surg Clin North Am 2013;21(1):33-42
2. Belloni-Fortina A, Piaserico S, Tonin E, et al. Melanoma and immunosuppression. Dermatology 2009;218(1):88; author reply 89
3. Houghton AN, Polsky D. Focus on melanoma. Cancer Cell 2002;2(4):275-8
4. Ehrlich P. U ̈ber den jetzigen stand der karzinomforschun. Ned Tijdschr Geneeskd 1909;5:273-90
5. Muul LM, Spiess PJ, Director EP, et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987;138(3):989-95
6. Clark WH Jr., Elder DE, Guerry Dt, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81(24):1893-904
7. Clemente CG, Mihm MC Jr., Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77(7):1303-10
8. Tefany FJ, Barnetson RS, Halliday GM, et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991;97(2):197-202
9. Al-Batran SE, Rafiyan MR, Atmaca A, et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005;65(9):3937-41
10. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 2006;6(10):715-27
11. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4(11):839-49
12. Mansfield AS, Holtan SG, Grotz TE, et al. Regional immunity in melanoma: Immunosuppressive changes precede nodal metastasis. Mod Pathol 2011;24(4):487-94
13. Koziner B, Cosimi AB, Bloch KJ. Distribution of latex-ingesting cells, T cells, and B cells in the peripheral blood of patients with malignant melanoma. J Natl Cancer Inst 1975;55(6):1295-9
14. McKay K, Moore PC, Smoller BR, et al. Association between natural killer cells and regression in melanocytic lesions. Human Pathol 2011;42(12):1960-4
15. Gerloni M, Zanetti M. CD4 T cells in tumor immunity. Springer Semin Immunopathol 2005;27(1):37-48
16. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174(5):2591-601
17. Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007;109(12):5346-54
18. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207(3):637-50
19. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112(2):362-73
20. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3(3):253-7
21. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008;112(13):4953-60
22. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173(2):1444-53
23. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006;107(6):2409-14
24. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA- 4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)- producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190(3):355-66
25. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194(6):823-32
26. Haanen JB, Baars A, Gomez R, et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006;55(4):451-8
27. Zippelius A, Batard P, Rubio-Godoy V, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res 2004;64(8):2865-73
28. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114(8):1537-44
29. Baitsch L, Baumgaertner P, Devevre E, et al. Exhaustion of tumor-specific CD8 (+) T cells in metastases from melanoma patients. J Clin Invest 2011;121(6):2350-60
30. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439(7077):682-7
31. Crawford A, Macleod M, Schumacher T, et al. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 2006;176(6):3498-506
32. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010;1183:38-57
33. Matsushita T, Yanaba K, Bouaziz JD, et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008;118(10):3420-30
34. Ladanyi A, Kiss J, Mohos A, et al. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 2011;60(12):1729-38
35. Martinez-Escribano JA, Hernandez-Caselles T, Campillo JA, et al. Changes in the number of CD80 (+), CD86(+), and CD28(+) peripheral blood lymphocytes have prognostic value in melanoma patients. Human Immunol 2003;64(8):796-801
36. Genc K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997;99(11):2664-71
37. Bijl M, Horst G, Limburg PC, et al. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001;60(5):523-6
38. Freeman GJ, Boussiotis VA, Anumanthan A, et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995;2(5):523-32
39. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/ Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995;80(5):707-18
40. DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010;184(7):4006-16
41. Carpenter EL, Mick R, Rech AJ, et al. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 2009;15(13):4277-87
42. Roberts DJ, Franklin NA, Kingeter LM, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 2010;33(8):769-79
43. Jean D, Gershenwald JE, Huang S, et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998;273(26):16501-8
44. Staquicini FI, Tandle A, Libutti SK, et al. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/ MUC18-dependent interaction: Evidence from mice and humans. Cancer Res 2008;68(20):8419-28
45. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1(5):459-65
46. Vogel LA, Lester TL, Van Cleave VH, et al. Inhibition of murine B1 lymphocytes by interleukin-12. Eur J Immunol 1996;26(1):219-23
47. Simon GC, Martin RJ, Smith S, et al. Up-regulation of MUC18 in airway epithelial cells by IL-13: Implications in bacterial adherence. Am J Respiratory Cell Mol Biol 2011;44(5):606-13
48. Lauerova L, Dusek L, Simickova M, et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002;49(3):159-66
49. Le Maux Chansac B, Moretta A, Vergnon I, et al. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 2005;175(9):5790-8
50. Moretta L, Moretta A. Unravelling natural killer cell function: Triggering and inhibitory human NK receptors. EMBO J 2004;23(2):255-9
51. Lanier LL. Turning on natural killer cells. J Exp Med 2000;191(8):1259-62
52. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285(5428):727-9
53. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14(2):123-33
54. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003;198(4):557-67
55. Fregni G, Perier A, Pittari G, et al. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 2011;17(9):2628-37
56. Pietra G, Manzini C, Vitale M, et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 2009;21(7):793-801
57. Gorelik E, Wiltrout RH, Okumura K, et al. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 1982;30(1):107-12
58. Takeda K, Nakayama M, Sakaki M, et al. IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J Leukocyte Biol 2011;90(4):777-85
59. Vieira PL, de Jong EC, Wierenga EA, et al. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000;164(9):4507-12
60. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature reviews Immunology 2003;3(2):133-46
61. Wong JL, Mailliard RB, Moschos SJ, et al. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother 2011;34(3):270-8
62. Carlsten M, Bjorkstrom NK, Norell H, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 2007;67(3):1317-25
63. Bottino C, Moretta L, Moretta A. NK cell activating receptors and tumor recognition in humans. Curr Top Microbiol Immunol 2006;298:175-82
64. Konjevic G, Mirjacic Martinovic K, Vuletic A, et al. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007;24(1):1-11
65. Balsamo M, Scordamaglia F, Pietra G, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA 2009;106(49):20847-52
66. Casado JG, Pawelec G, Morgado S, et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 2009;58(9):1517-26
67. Balsamo M, Pietra G, Vermi W, et al. Melanoma immunoediting by NK cells. Oncoimmunology 2012;1(9):1607-9
68. Markel G, Ortenberg R, Seidman R, et al. Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother 2010;59(2):215-30
69. Gauci CL, Alexander P. The macrophage content of some human tumours. Cancer Lett 1975;1(1):29-32
70. Ellyard JI, Quah BJ, Simson L, et al. Alternatively activated macrophage possess antitumor cytotoxicity that is induced by IL-4 and mediated by arginase-1. J Immunother 2010;33(5):443-52
71. Bugelski PJ, Kirsh RL, Sowinski JM, et al. Changes in the macrophage content of lung metastases at different stages in tumor growth. Am J Pathol 1985;118(3):419-24
72. Bugelski PJ, Corwin SP, North SM, et al. Macrophage content of spontaneous metastases at different stages of growth. Cancer Res 1987;47(15):4141-5
73. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992;13(7):265-70
74. Stuehr DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989;169(5):1543-55
75. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 2002;196(3):254-65
76. Byrne SN, Knox MC, Halliday GM. TGFbeta is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol Cell Biol 2008;86(1):92-7
77. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: The macrophage connection. J Leukocyte Biol 1998;64(3):275-90
78. Manrique SZ, Correa MA, Hoelzinger DB, et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. J Exp Med 2011;208(7):1485-99
79. Leek RD, Landers RJ, Harris AL, et al. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999;79(5-6):991-5
80. Ono M, Torisu H, Fukushi J, et al. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol 1999;43(Suppl):S69-71
81. Torisu H, Ono M, Kiryu H, et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1alpha. Int J Cancer 2000;85(2):182-8
82. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008;29(3):372-83
83. Gerlini G, Urso C, Mariotti G, et al. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin immunol 2007;125(2):184-93
84. Gerlini G, Di Gennaro P, Mariotti G, et al. Human Langerhans cells are immature in melanoma sentinel lymph nodes. Blood 2012;119(20):4807-8; author reply 09-10
85. McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: Linking innate and adaptive immunity. J Virol 2005;79(1):17-27
86. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002;195(6):695-704
87. Caux C, Massacrier C, Vanbervliet B, et al. Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int Immunol 1994;6(8):1177-85
88. Walzer T, Dalod M, Robbins SH, et al. Natural-killer cells and dendritic cells: "l'union fait la force". Blood 2005;106(7):2252-8
89. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5(4):405-11
90. Capobianco A, Rovere-Querini P, Rugarli C, et al. Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells. Int J cancer 2006;119(12):2861-9
91. Ali OA, Emerich D, Dranoff G, et al. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Medicine 2009;1(8):8ra19
92. Matheoud D, Baey C, Vimeux L, et al. Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model. PloS One 2011;6(4):e19104
93. Moretti S, Pinzi C, Spallanzani A, et al. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 1999;84(2):160-8
94. Mantovani A. Cancer: Inflaming metastasis. Nature 2009;457(7225):36-7
95. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6(5):447-58
96. Albino AP, Davis BM, Nanus DM. Induction of growth factor RNA expression in human malignant melanoma: Markers of transformation. Cancer Res 1991;51(18):4815-20
97. Krasagakis K, Tholke D, Farthmann B, et al. Elevated plasma levels of transforming growth factor (TGF)- beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 1998;77(9):1492-4
98. Van Belle P, Rodeck U, Nuamah I, et al. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 1996;148(6):1887-94
99. Diaz-Valdes N, Basagoiti M, Dotor J, et al. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 2011;71(3):812-21
100. Javelaud D, Alexaki VI, Mauviel A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 2008;21(2):123-32
101. Critchley-Thorne RJ, Simons DL, Yan N, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A 2009;106(22):9010-15
102. Konjevic G, Mirjacic Martinovic K, Vuletic A, et al. In-vitro IL-2 or IFN-alpha-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients. Melanoma Res 2010;20(6):459-67
103. Yoshimoto T, Morishima N, Mizoguchi I, et al. Antiproliferative activity of IL-27 on melanoma. J Immunol 2008;180(10):6527-35
104. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454(7203):436-44
105. Bedogni B, Warneke JA, Nickoloff BJ, et al. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 2008;118(11):3660-70
106. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62(24):7328-34
107. Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symposium Proc 2005. 10(2):153-63
108. Schwarz T, Luger TA. Effect of UV irradiation on epidermal cell cytokine production. J Photochem Photobiol B 1989;4(1):1-13
109. Marathe GK, Johnson C, Billings SD, et al. Ultraviolet B radiation generates platelet-activating factor-like phospholipids underlying cutaneous damage. J Biol Chem 2005;280(42):35448-57
110. Pei Y, Barber LA, Murphy RC, et al. Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis. J Immunol 1998;161(4):1954-61
111. Walterscheid JP, Ullrich SE, Nghiem DX. Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J Exp Med 2002;195(2):171-9
112. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005;571(1-2):185-205
113. Lee JT, Herlyn M. Microenvironmental influences in melanoma progression. J Cell Biochem 2007;101(4):862-72
114. Hsu MY, Meier F, Herlyn M. Melanoma development and progression: A conspiracy between tumor and host. Differentiation 2002;70(9-10):522-36
115. Minkis K, Kavanagh DG, Alter G, et al. Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNAtransfected dendritic cells. Cancer Res 2008;68(22):9441-50
116. Ruf W. Tissue factor and PAR signaling in tumor progression. Thrombosis Res 2007;120(Suppl2):S7-12
117. Melnikova VO, Villares GJ, Bar-Eli M. Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer microenviron 2008;1(1):103-11
118. Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: A place in history or in the future. Postgrad Med J 2003;79(938):672-80
119. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement. Biomed Pharmacother 2007;61(6):299-305
120. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: Lessons learned from melanoma. Curr Opin Immunol 2001;13(2):134-40
121. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4(3):321-7
122. Ernstoff CC, Urba W, Flaherty L, et al. A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209-2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts). J Clin Oncol 2005;23(16S):abstract # 7504
123. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115(16):3670-9
124. Brahmer JR., Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65
125. Topalian SL, Hodi FS, Brahmer JR., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
126. Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004;16(6):542-6
127. Rosenberg L, Duguid WP, Brown RA. Development of experimental cancer in the head of the pancreas by surgical induction of tissue injury. Am J Surg 1984;147(1):146-51
128. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271(12):907-13
129. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105-16
130. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005;23(27):6747-55
131. Davar D, Saul M, Tarhini AA, et al. High-dose interleukin-2 (HD IL-2) in the treatment of advanced melanoma: The University of Pittsburgh experience. J Clin Oncol 2013;31(Suppl):abstract 9075
132. Maellaro E, Pacenti L, Del Bello B, et al. Different effects of interferon-alpha on melanoma cell lines: A study on telomerase reverse transcriptase, telomerase activity and apoptosis. Br J Dermatol 2003;148(6):1115-24
133. Fleischmann CM, Stanton GJ, Fleischmann WR Jr.. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J Interferon Cytokine Res 1996;16(10):805-12
134. Davar D, Tarhini AA, Kirkwood JM. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol 2013;31(3):237-50
135. Yang YF, Zou JP, Mu J, et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997;57(18):4036-41
136. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
137. Le Scolan E, Zhu Q, Wang L, et al. Transforming growth factor-beta suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation. Cancer Res 2008;68(9):3277-85
138. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26
139. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic Tlymphocyte antigen-4. J Clin Oncol 2005;23(25):6043-53
140. Harvey B, Lee D, Gaudin AF, et al. Changes in the quality of life of advanced melanoma patients after 12 weeks of treatment with ipilimumab compared to gp100 in a phase III clinical trial. J Clin Oncol 2013;31(Suppl):abstract 9084
141. Chandra S, Madden K, Kannan R, et al. Evaluating the safety of anti-CTLA-4 therapy in the elderly with unresectable melanoma. J Clin Oncol 2013;31
142. Ribas A, Antonia SJ, Sosman JA, et al. Results of a phase II trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients with advanced melanoma. J Clin Oncol 2007;25(Suppl18):abstract 3000
143. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23(35):8968-77
144. Tarhini AA, Iqbal F. CTLA-4 blockade: Therapeutic potential in cancer treatments. Onco Targets Ther 2010;3:15-25
145. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293-7
146. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006;119(2):317-27
147. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 2013;31(Suppl):abstract 9010
148. Sznol M, Kluger HM, Hodi FS, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013;31(Suppl): Abstract CRA9006
149. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134-44
150. Sierro SR, Donda A, Perret R, et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 2011;41(8):2217-28
151. Mangsbo SM, Sandin LC, Anger K, et al. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010;33(3):225-35
152. Li B, VanRoey M, Wang C, et al. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009;15(5):1623-34
153. Hodi FS, Lee SJ, McDermott DF, et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. J Clin Oncol 2013;31(Suppl):abstract CRA9007
154. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 2013;369(2):122-33
155. Kudchadkar RR, Gibney GT, Weber J, et al. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Clin Oncol 2013;31(Suppl): Abstract 9079
156. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/ C9190. J Clin Oncol 2000;18(12):2444-58